SCHEMBL3449010

SCHEMBL3449010

O=C(O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2nccn2)c1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 8/20 0.45
CSNK2A2 P19784 2/20 0.45
CSNK2B P67870 2/20 0.45
XDH P47989 1/20 0.43
SLC22A12 Q96S37 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
EGFR P00533 2/20 0.41
AURKA O14965 2/20 0.40
JAK2 O60674 1/20 0.40
AURKB Q96GD4 1/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
MAPK1 P28482 2/20 0.40
STK17B O94768 1/20 0.39
STK17A Q9UEE5 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3450058 0.87 XDH (0.42) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3448523 0.87 P2RY12 (0.43) CSNK2A1L3MBTL1EGFRABL1BCR
SCHEMBL3449152 0.87 XDH (0.43) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3447674 0.86 JAK3 (0.43) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3449234 0.86 XDH (0.43) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3449473 0.86 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3448584 0.86 CSNK2A1 (0.44) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3451174 0.85 JAK3 (0.44) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3447741 0.85 JAK3 (0.44) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12
SCHEMBL3449596 0.85 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BXDHSLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CSNK2A1 1858/4885CSNK2A2 1967/4885CSNK2B 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.